#Bioretec #Finland #Tampere #Orthopedic Implants #RemeOs

Bioretec Ltd Announces Financial Reporting Schedule for 2026

Bioretec Ltd, a leading Finnish company specializing in medical devices, has laid out its financial reporting schedule and the date for its upcoming Annual General Meeting (AGM) set for 2026. Recognized for its innovative approaches in orthopedic care, Bioretec focuses on developing biodegradable implant technologies that enhance patient healing processes. The company aims to provide stakeholders with transparent updates through a series of financial reports throughout the year.

In 2025, the company will release its financial results on key dates:

• - February 13, 2026: The financial statements bulletin for the period of January to December 2025 will be shared.
• - March 13, 2026: The comprehensive annual report, complete with the Board of Directors' report and the financial statements for 2025, will be published.
• - May 14, 2026: A business review covering January to March 2026 will be available for review.
• - August 13, 2026: The half-year report detailing performance from January to June 2026 will be released.
• - November 12, 2026: The business review for the period of January to September 2026 will be distributed.

All financial reports will be accessible as company releases on the official Bioretec website, ensuring investors and interested parties can conveniently access the necessary information. The thorough dissemination of these reports signifies Bioretec's commitment to upholding transparency and diligent governance practices.

The Annual General Meeting of Bioretec is scheduled for May 8, 2026, where shareholders will convene to discuss the company's progress and future directions. The Board of Directors is expected to announce more details on the AGM closer to the date, allowing for adequate planning and participation from shareholders around the globe.

Bioretec has gained recognition not only for its financial excellence but also for its innovative contributions to orthopedic medical technology. The company operates internationally, utilizing unique biodegradable materials in its products to promote better healing outcomes for patients undergoing orthopedic surgeries.

One of the flagship product lines introduced by Bioretec, RemeOs™, represents the next generation in orthopedic implants. Constructed from advanced magnesium alloys and hybrid composites, these implants are engineered to integrate seamlessly with bone tissue as they are absorbed, eventually being replaced by new bone, thereby eliminating the need for removal surgeries. Official market authorization for the RemeOs products was obtained in the U.S. in March 2023, following the grant of the CE mark approval from Europe in January 2025.

Another significant product line, Activa, features fully bioabsorbable orthopedic implants made from a proprietary PLGA material that has received approvals from both the CE and FDA. These implants span a wide range of applications suitable for both adult and pediatric patients, emphasizing Bioretec's dedication to developing safe, efficient medical solutions.

Bioretec Ltd continues to lead the way in orthopedic treatment innovations, focusing on healing through absorption and patients’ comfort. With strategic planning and a commitment to advancing medical technologies, Bioretec aims to enhance the standard of care for orthopedic patients worldwide. To explore more about their innovative products and the upcoming financial reports, visit Bioretec's official site.